Numerion Labs vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 52)
Numerion Labs logo

Numerion Labs

ChallengerLife Sciences & BioTech

AI-Driven Small Molecule Drug Discovery

Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones; rebranded Oct 2025 with new APEX platform for hyper-scalable virtual library screening.

AI VisibilityBeta
Overall Score
C52
Category Rank
#68 of 198
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
51
Perplexity
49
Gemini
55

About

Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core technology, AtomNet, is a convolutional neural network trained on vast datasets of protein-ligand interactions to predict binding affinity and drug-likeness at scale. In October 2025, Atomwise rebranded as Numerion Labs, reflecting a sharpened strategic focus on ultra-fast virtual screening and the development of its APEX platform for hyper-scalable chemical library screening — a capability validated in partnership with NVIDIA.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

52
Overall Score
74
#68
Category Rank
#11
81
AI Consensus
68
stable
Trend
stable
51
ChatGPT
71
49
Perplexity
68
55
Gemini
80
47
Claude
77
52
Grok
69

Key Details

Category
AI-Driven Small Molecule Drug Discovery
AI-Enabled Precision Medicine
Tier
Challenger
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.